FY2028 EPS Estimates for TSE:ONC Decreased by HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – HC Wainwright cut their FY2028 EPS estimates for shares of Oncolytics Biotech in a report released on Monday, March 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.57 for the year, down from their previous forecast of $0.60. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2029 earnings at $1.06 EPS.

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Trading Down 3.2 %

Shares of ONC stock opened at C$0.90 on Wednesday. Oncolytics Biotech has a 12-month low of C$0.86 and a 12-month high of C$2.08. The company has a market capitalization of C$69.37 million, a P/E ratio of -2.51 and a beta of 1.35. The firm has a 50-day moving average price of C$1.11 and a 200 day moving average price of C$1.30. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.